Insight

Photo taken from Fred Saad/X

Sep 26, 2024, 12:37

Exclusive Interview With Fred Saad

MediaMedic shared on LinkedIn:

“Exclusive Insights on mHSPC Treatment: Interview with Fred Saad.

In a recent Media Medic interview, our colleague El Bachir Mourabit had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment.

Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival.

He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.”

Source: MediaMedic/LinkedIn

abiraterone androgen deprivation therapy apalutamide cancer chemotherapy darolutamide El Bachir Mourabit Enzalutamide Fred Saad MediaMedic mHSPC treatment OncoDaily Oncology

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage